Lista de obras -

'No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia': authors' response

artículo científico publicado en 2017

A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data

artículo científico publicado en 2020

Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patients

artículo científico publicado en 2018

Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study.

artículo científico publicado en 2017

Agents intervening against delirium in the intensive care unit (AID-ICU) - Protocol for a randomised placebo-controlled trial of haloperidol in patients with delirium in the ICU

artículo científico publicado en 2019

Associations between P3a and P3b amplitudes and cognition in antipsychotic-naïve first-episode schizophrenia patients

artículo científico publicado en 2018

Associations between cortical thickness and auditory verbal hallucinations in patients with schizophrenia: A systematic review

article

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

artículo científico publicado en 2018

Cortical structures and their clinical correlates in antipsychotic-naïve schizophrenia patients before and after 6 weeks of dopamine D2/3 receptor antagonist treatment

artículo científico publicado en 2018

Decreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode Schizophrenia

artículo científico publicado en 2010

Diagnostic stability and long-term symptomatic and functional outcomes in first-episode antipsychotic-naïve patients with schizophrenia

artículo científico publicado en 2019

Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12-43 years

artículo científico publicado en 2020

Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial

artículo científico publicado en 2016

Erratum to: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.

artículo científico publicado en 2018

Extrastriatal dopamine D2/3 receptors and cortical grey matter volumes in antipsychotic-naïve schizophrenia patients before and after initial antipsychotic treatment

artículo científico publicado en 2016

F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST.

artículo científico publicado en 2018

Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology

artículo científico publicado en 2016

Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade

artículo científico publicado en 2015

Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis

scientific article published on 07 October 2018

Heritability of Cerebral Blood Flow and the Correlation to Schizophrenia Spectrum Disorders: A Pseudo-continuous Arterial Spin Labeling Twin Study

scientific article published on 01 October 2019

Heritability of Memory Functions and Related Brain Volumes: A Schizophrenia Spectrum Study of 214 Twins

Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol

scientific article published on 30 April 2020

Increased use of coercive procedures and prolonged hospitalization in compulsory admitted psychotic patients, who refuse antipsychotic medication

scientific article published on 06 January 2020

Multimodal assessment of white matter microstructure in antipsychotic-naïve schizophrenia patients and confounding effects of recreational drug use

scientific article published on 06 January 2020

No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia

artículo científico publicado en 2017

Non-pharmacological modulation of cerebral white matter organization: A systematic review of non-psychiatric and psychiatric studies

scientific article published on 14 March 2018

Patterns of Cortical Structures and Cognition in Antipsychotic-Naïve Patients With First-Episode Schizophrenia: A Partial Least Squares Correlation Analysis

artículo científico publicado en 2018

Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users

scholarly article by Lone Baandrup et al published 15 March 2018 in Cochrane Database of Systematic Reviews

Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort)

scientific article published on 19 July 2019

S15. HERITABILITY AND CORRELATION TO SCHIZOPHRENIA SPECTRUM DISORDERS OF CEREBRAL BLOOD FLOW MEASURED BY PSEUDO-CONTINUOUS ARTERIAL SPIN LABELING IN DANISH TWINS

Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine

artículo científico publicado en 2010

Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade - An exploratory study

scientific article published on 08 February 2019

Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment

artículo científico publicado en 2016

T88. THE IMPACT OF AGE OF ONSET AND ILLNESS DURATION ON WHITE MATTER AND COGNITION TRAJECTORIES IN SCHIZOPHRENIA: A 7-YEAR FOLLOW-UP STUDY ACROSS MULTIPLE TIME-POINTS

T97. PATTERNS OF COGNITIVE FUNCTION ARE UNIQUELY ASSOCIATED WITH WHITE MATTER-MICROSTRUCTURE IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS

TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical tri

artículo científico publicado en 2017

The impact of schizophrenia and intelligence on the relationship between age and brain volume

Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis

scientific article published on 16 September 2019

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology

artículo científico publicado en 2016

White matter maturation during 12 months in individuals at ultra-high-risk for psychosis.

artículo científico publicado en 2017

Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultra-high risk for psychosis

artículo científico publicado en 2019

Lista de obras de

'No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia': authors' response

A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data

Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patients

Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study.

Agents intervening against delirium in the intensive care unit (AID-ICU) - Protocol for a randomised placebo-controlled trial of haloperidol in patients with delirium in the ICU

Associations between P3a and P3b amplitudes and cognition in antipsychotic-naïve first-episode schizophrenia patients

Associations between cortical thickness and auditory verbal hallucinations in patients with schizophrenia: A systematic review

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Cortical structures and their clinical correlates in antipsychotic-naïve schizophrenia patients before and after 6 weeks of dopamine D2/3 receptor antagonist treatment

Decreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode Schizophrenia

Diagnostic stability and long-term symptomatic and functional outcomes in first-episode antipsychotic-naïve patients with schizophrenia

Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12-43 years

Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial

Erratum to: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.

Extrastriatal dopamine D2/3 receptors and cortical grey matter volumes in antipsychotic-naïve schizophrenia patients before and after initial antipsychotic treatment

F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST.

Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology

Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade

Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis

Heritability of Cerebral Blood Flow and the Correlation to Schizophrenia Spectrum Disorders: A Pseudo-continuous Arterial Spin Labeling Twin Study

Heritability of Memory Functions and Related Brain Volumes: A Schizophrenia Spectrum Study of 214 Twins

Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol

Increased use of coercive procedures and prolonged hospitalization in compulsory admitted psychotic patients, who refuse antipsychotic medication

Multimodal assessment of white matter microstructure in antipsychotic-naïve schizophrenia patients and confounding effects of recreational drug use

No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia

Non-pharmacological modulation of cerebral white matter organization: A systematic review of non-psychiatric and psychiatric studies

Patterns of Cortical Structures and Cognition in Antipsychotic-Naïve Patients With First-Episode Schizophrenia: A Partial Least Squares Correlation Analysis

Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users

Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort)

S15. HERITABILITY AND CORRELATION TO SCHIZOPHRENIA SPECTRUM DISORDERS OF CEREBRAL BLOOD FLOW MEASURED BY PSEUDO-CONTINUOUS ARTERIAL SPIN LABELING IN DANISH TWINS

Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine

Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade - An exploratory study

Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment

T88. THE IMPACT OF AGE OF ONSET AND ILLNESS DURATION ON WHITE MATTER AND COGNITION TRAJECTORIES IN SCHIZOPHRENIA: A 7-YEAR FOLLOW-UP STUDY ACROSS MULTIPLE TIME-POINTS

T97. PATTERNS OF COGNITIVE FUNCTION ARE UNIQUELY ASSOCIATED WITH WHITE MATTER-MICROSTRUCTURE IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS

TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical tri

The impact of schizophrenia and intelligence on the relationship between age and brain volume

Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology

White matter maturation during 12 months in individuals at ultra-high-risk for psychosis.

Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultra-high risk for psychosis